iShares Nasdaq Biotechnology (IBB)

Add to Watchlists Create an Alert
276.55 +2.43  +0.89% NASDAQ Aug 29, 8:00PM BATS Real time Currency in USD
View Full Chart
IBB Price Chart

IBB Description

iShares Nasdaq Biotechnology is a long only equity fund managed by iShares that tracks the NASDAQ Biotechnology TR USD index and has 5.545B USD assets under management. It has an expected distribution yield of 0.20%, a Prospective PE Ratio of 25.95, and a Prospective Price to Book Value of 6.220. The fund has a net expense ratio of 0.48%, turns over its positions 39.00% per year, and is traded on the NASDAQ.

Benchmark Index: NASDAQ Biotechnology TR USD

IBB Key Info

Expense Ratio (7-31-14) 0.48%
Assets Under Management (8-29-14) 5.545B
30-Day Average Volume (8-29-14) 1.023M
Net Asset Value (8-29-14) 276.56
Discount or Premium to NAV (8-29-14) 0.00%
Turnover Ratio (3-31-14) 39.00%

IBB Asset Allocation

Type % Net % Long % Short
Cash 0.00% 0.00% 0.00%
Stock 99.88% 99.88% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.12% 0.12% 0.00%
As of Aug. 27, 2014

IBB Region Exposure

Americas 94.78%
North America 94.78%
Latin America 0.00%
Greater Europe 5.16%
United Kingdom 1.63%
Europe Developed 3.53%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.06%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.06%
Market Classification
% Developed Markets 99.94%
% Emerging Markets 0.06%
As of Aug. 29, 2014
Region breakdown data is calculated by using the long position holdings of the portfolio.

IBB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Aug. 27, 2014

IBB Stock Market Capitalization

Giant 35.81%
Large 23.48%
Medium 21.28%
Small 9.68%
Micro 9.63%
As of Aug. 27, 2014
View More Holdings

IBB Top 10 Holdings

Name % Weight Price Chg %
Gilead Sciences Inc 9.40% 107.56 +0.05%
Celgene Corp 8.79% 95.02 +0.34%
Amgen Inc 8.44% 139.38 +0.50%
Biogen Idec Inc 7.63% 343.04 +0.53%
Alexion Pharmaceuticals Inc 6.60% 169.29 +0.58%
Vertex Pharmaceuticals Inc 4.57% 93.57 +0.83%
Regeneron Pharmaceuticals Inc 4.05% 350.46 +1.02%
Illumina Inc 4.04% 179.36 +0.16%
Mylan Inc 3.42% 48.60 +0.98%
Biomarin Pharmaceutical Inc 2.20% 71.22 +2.30%
As of Aug. 27, 2014
Get Quote for
Advertisement

IBB Risk Info

Beta 0.9284
Max Drawdown (2-5-01 to 8-29-14) 62.85%
30 Day Average Volatility 18.22%

IBB Fundamentals

Distribution Yield TTM (8-29-14) 0.20%
Distribution Yield (Prospective) 0.24%
PE Ratio (Prospective) 25.95
PS Ratio (Prospective) 7.003
Price to Book Value (Prospective) 6.220
ROE 7.13%
ROA 0.52%
Number of Holdings 120.00
As of Aug. 27, 2014

IBB Growth Estimates

Forecasted 5 Yr Earnings Growth 15.77%
Forecasted Book Value Growth 10.36%
Forecasted Cash Flow Growth 13.34%
Forecasted Earnings Growth 25.06%
Forecasted Revenue Growth 12.57%
As of Aug. 27, 2014

IBB Performance

  Returns Total Returns
1M 8.54% 8.54%
3M 14.77% 14.95%
6M 4.59% 4.75%
1Y 41.26% 41.47%
3Y 190.6% 192.6%
5Y 251.0% 255.5%
As of Aug. 29, 2014

IBB Flows

1M 15.96M
3M -178.04M
6M -418.98M
YTD 226.71M
1Y 498.08M
3Y 1.217B
5Y 751.13M
As of Aug. 31, 2014
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Start My Free Trial"}}

Already a {{root.upsell.info.tier_name}} Member? Sign in here.